Table 3.
Comparison of periprocedural complications in the 3 patient groups receiving DOACs
| Complications | (Total No. of Patients = 474) | |||||||
|---|---|---|---|---|---|---|---|---|
| Acenocoumarol, n = 136 (28.7%) | Rivaroxaban, n = 110 (23.2%) | Apixaban, n = 114 (24.1%) | Dabigatran, n = 114 (24.1%) | |||||
| N | % | N | % | N | % | N | % | |
| None | 131 | 96.3 | 105 | 98.2 | 111 | 97.3 | 111 | 97.4 |
| Major complications | 3 | 2.2 | 0 | 0.0 | 0 | 0.0 | 1 | 0.9 |
| TIA | 1 | 0.7 | 0 | 0.0 | 0 | 0.0 | 1 | 0.9 |
| Tamponade | 1 | 0.7 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| Subcapsular renal hematoma | 1 | 0.7 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| Minor complications | 2 | 1.5 | 2 | 1.8 | 3 | 2.6 | 2 | 1.8 |
| Pseudoaneurysm | 1 | 0.7 | 0 | 0.0 | 0 | 0.0 | 1 | 0.9 |
| Pericardial effusion | 0 | 0.0 | 2 | 1.8 | 2 | 1.8 | 0 | 0.0 |
| Femoral AV fistula | 0 | 0.0 | 0 | 0.0 | 1 | 0.9 | 0 | 0.0 |
| Groin hematoma | 1 | 0.7 | 0 | 0.0 | 0 | 0.0 | 1 | 0.9 |
Abbreviations: AV, arteriovenous; DOACs, direct oral anticoagulants; TIA, transient ischemic attack.